UBS voiced cautiousness on Boot Barn Holdings (BOOT) ahead of its earnings release on Wednesday.
→ Google Traductor
This article is excerpted from Tom Yeung’s Profit & Protection newsletter. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . Growth Investing Works On Tuesday, I introduced the Profit & Protection playbook — a good, hard look into beating the markets with data. The big takeaway from that newsletter? Growth investing works. Stocks with high expected growth rates (both sales and earnings) and past growth tend to outperform over the following twelve months. That’s no news to venture capitalists or my Hypergrowth Investing colleague, Luke Lango. But there was a wrinkle: Turnarounds do even better. Stocks that had the worst sales growth in the prior year outperformed their high-growth counterparts by a 1.4-to-1 ratio. I can practically see Warren Buffett and InvestorPlace analyst Eric Fry smiling. But if you’re tired of all this theoretical fluff, I don’t blame you. We’re here for profits, not a lesson in data science or fortune-telling. So today, we’re going to use the Profit & Protection playbook to identify five promising growth stocks that look set to ride out the upcoming 6 to 12 months.
→ Google Traductor
Upgrades For Coupang Inc (NYSE: CPNG ), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99. According to Guggenheim, the prior rating for NextGen Healthcare Inc (NASDAQ: NXGN ) was changed from Neutral to Buy. In the third quarter, NextGen Healthcare showed an EPS of $0.24, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $21.87 and a 52-week-low of $13.64. At the end of the last trading period, NextGen Healthcare closed at $19.52. According to CLSA, the prior rating for Melco Resorts and Entertainment Ltd (NASDAQ: MLCO ) was changed from Outperform to Buy. For the first quarter, Melco Resorts and Enter had an EPS of $0.37, compared to year-ago quarter EPS of $0.44. The stock has a 52-week-high of $19.18 and a 52-week-low of $5.12. At the end of the last trading period, Melco Resorts and Enter closed at $5.19. Raymond James upgraded the previous rating for Jounce Therapeutics Inc (NASDAQ: JNCE ) from Outperform to Strong Buy.
→ Google Traductor